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Abstract  (180 words) 14 
 15 
Objective 16 
 This study investigated trial consultations to identify whether and to what extent discussions of 17 
retention are present.  18 
 19 
Study design and setting This embedded mixed-methods study design included a purposive 20 
sample of audio-recorded trial consultations obtained from four sites of a large multicentre UK 21 
based surgical RCT.  Study participants included potential trial participants, trial Surgeons and 22 
Research Nurses.   23 
 24 
Results: Forty-four participants were included in this study: Potential trial participants (n=37); 25 
trial Surgeons (n=4); and Research Nurses (n=3). Analysis revealed no discussion of retention 26 
across 79% of consultations. Of the remaining 21% where discussions of retention were present, 27 
only 3% (maximum) of the  conversation related to retention. There was some evidence of good 28 
practice but on the whole the discussions contained inaccuracies about timing and delivery of 29 
questionnaires and the right to withdraw often highlighted  without providing trial 30 
consequences.   31 
Conclusion: This study is the first to explore trial consultations for discussions of retention. It 32 
suggests that there may be room for improvement within current practice. Further research is 33 
required to determine the generalizability of the findings reported to other clinical trials.   34 







Clinical trials are regarded as the cornerstone of evidence-based health care as if conducted 39 
rigorously they offer unbiased estimates of treatment effects. [1]  Yet despite their importance, 40 
there are significant methodological challenges in ensuring trials are done well.  Recruitment and 41 
retention have been identified as amongst the top priorities for research amongst UK trialists [2]. 42 
Whilst there is now a significant body of research asking various methodological questions about 43 
recruitment and using an array of methods to answer these questions, the same cannot be said 44 
for retention.   45 
Retaining participants in clinical trials remains a significant challenge [3]. Recent work suggests 46 
that 50% of all trials have loss to follow up of more than 11% [4].  Missing data in trials is of 47 
concern as it has the potential to introduce bias and make the trial results unreliable or in some 48 
cases unusable in practice. Missing data is particularly problematic if the missingness is not at 49 
random. In other words, if there is differential loss to follow up in the control arm versus the 50 
intervention, or amongst people who are more unwell. If the missingness is at random it can still 51 
cause a problem. It has been proposed that less than 5% missing data is not problematic but 52 
more than 20% poses serious threats to validity – yet in some cases even less than 20% 53 
completion rates is a problem [4].   When data is missing, statistical analysis methods (such as 54 
complete case analysis or imputation) are used to address the problem. However it seems much 55 
more sensible to mitigate problems of missing data by designing effective approaches and 56 
strategies to maximise data collection. Without effective ways of reducing loss to follow up, trials 57 
currently include inflated sample sizes at baseline to allow for trial participants who will not be 58 
retained. Therefore, recruiting extra participants to account for low retention is a resource poor 59 
solution which costs more, takes longer, but ultimately potentially exposes additional patients to 60 
risks they needn’t be exposed to or forgoes the opportunity to provide effective treatments. 61 
A Cochrane review that aimed to identify interventions to improve retention in trials identified a 62 
range of studies using various approaches. Yet the only intervention with good evidence of 63 
benefit was monetary incentives to improve response to postal questionnaires [3].  It is of 64 
interest that most of the studies included in this review do not report patient involvement in the 65 
identification or development of the interventions under evaluation. This begs the question as to 66 
whether these retention interventions are fit for purpose.  A recent synthesis of qualitative 67 
studies that explored participant reasons for trial drop out summarised that retention is 68 
influenced by a complex interplay between participants own internal influences (e.g. beliefs and 69 




highlights the need to make participants more aware at the consenting stage of what can be 71 
expected by participating in the trial. 72 
A recent study analysed the information potential trial participants are provided with when 73 
considering trial participation and focussed on information about retention [7].  Within the 74 
sample analysed, only 16% included statements about the value of retention yet 98% frequently 75 
reiterated the patients right to withdraw [7]. Investigations of written trial information certainly 76 
provide a great starting point to offer improvements. Given the suggestion that patients very 77 
much value the wider conversation that these documents seek to support when considering 78 
recruitment there has been a ground swell in recent years exploring trial consultations for key 79 
aspects of trial recruitment (e.g. balancing options, explaining randomisation etc) [8,9].  This 80 
analysis of consultations for discussions of recruitment has been ongoing in some trials for over 81 
25 years and more recently has been developed into a key part of a complex intervention aimed 82 
to target recruitment to trial [10,11].  Using this approach of analysing discussions about trial 83 
participation between potential participant and clinical staff, our study aimed to explore 84 
whether and how discussions of retention are articulated during the initial conversations about 85 
trial participation. 86 
 87 
Methods  88 
This was a concurrent embedded mixed method study nested within an ongoing parent trial 89 
(ISRCTN55215960 and further information here:https://w3.abdn.ac.uk/hsru/C-90 
GALL/Public/Public/index.cshtml).  91 
 92 
Parent trial characteristics 93 
The parent trial was a Phase III pragmatic effectiveness trial comparing surgery to medical 94 
management for gallstone disease with a proposed total sample size of 430. Patients were 95 
approached by a consultant surgeon and/or a research nurse in a UK secondary care setting 96 
about participating in the trial. In advance of the trial starting recruitment locally each site 97 
received a site set up meeting from the Trial Manager. During this training site staff involved in 98 
recruitment of potential trial participants were informed of the follow-up schedule (i.e. timing of 99 
postal questionnaires) sent to participants and reinforced the importance of discussing this with 100 
potential trial participants during informed consent.  In addition to these initial meetings, sites 101 
received communication from the trial office through Newsletters and Investigator meetings 102 




process information was provided to every potential trial participant in a standardised Patient 104 
Information Leaflet (PIL) and supported through discussion with either/both a surgeon and 105 
research nurse.  The written information within the PIL contained a statement that indicated 106 
postal questionnaires will be sent for completion. Potential trial participants could take as much 107 
time as they needed to make their decision.  If a decision to participate was given, participants 108 
would be randomised to surgery or conservative management. Once randomised to the 109 
intervention, participants would be requested to complete and return postal questionnaires 110 
(which were sent centrally from the trial study office) at three, nine, 12 and 18-month intervals.  111 
Aggregate response rates across time points for questionnaire response varied from 57-80% at 112 
the time of conducting the study. The parent trial has standardised approaches administered 113 
centrally through the trial office that aim to improve the return of postal questionnaires.  These 114 
are as follows. Postal questionnaire for the desired time point is issued and if no response at 3 115 
weeks a reminder letter is issued. Following a further 3 weeks, if still no response a telephone 116 
call is implemented.  If the call is unsuccessful then a final reminder is issued. 117 
 118 
Recruitment and Sampling 119 
The parent trial had already received ethical approval for the audio-recording of trial 120 
consultations as part of the ongoing qualitative evaluation embedded at the trial design stage. 121 
Several trial sites were recording informed consent consultations. Units for sampling were 122 
individual sites. A purposive sample of four (out of a total of 18, of which seven were eligible) 123 
sites with varying levels of retention (assessed by postal questionnaire response percentage at 124 
three and nine months) were sampled to provide a variety of discussions from sites with varying 125 
retention patterns. Variability was further generated within our sample - as the audio-recordings 126 
included were heterogenous in terms of site, surgeon, research nurses and duration of 127 
consultation; in a bid to promote increased generalisability of findings.  However, maximum 128 
representation and diversity within consultation discussions were not possible due to the sample 129 
being convenience derived and time restrain limitations (as being conducted as a Masters degree 130 
project). To preserve anonymity, site names were anonymised and were labelled A, B, C, and D. 131 
Researchers aimed to analyse the 10 most recent (assuming that analysing most recent practices 132 
would be required if intending to implement a change based on findings) consultations where 133 
available; however, Site B had not yet reached 10 consultation recordings resulting in analysis of 134 
eight from that site. 135 
 136 





The major quantitative data for this embedded mixed methods study was provided by  the 139 
parent RCT in the form of response rates (presented as %) for the return of postal 140 
questionnaires. This data provides information on retention across the trial as a whole and at an 141 
individual site level.  142 
Audio-recordings of the consultations were transcribed verbatim and anonymised by redacting 143 
identifiable information. Data management and initial analytic coding were facilitated using 144 
Microsoft Excel. Analysis first took a deductive approach and entailed coding data transcripts 145 
into predefined categorical descriptions (such as ‘presence of discussion of retention’, discussion 146 
of questionnaires’, ‘discussion of withdrawal’, etc) taking a constant comparative approach.  The 147 
pre-defined codes were developed by all members of the research team based on research aims 148 
and informed by existing literature on information that may be important for retention [7]. 149 
Initial coding was conducted by PT with 25% check by KG with any discrepancies in agreement 150 
discussed with an arbiter (ED). Data was analysed inductively through a broad thematic process 151 
to identify overarching similar and divergent patterns across consultations. The development of 152 
the inductive themes was led by PT with input and discussion from the rest of the team to agree 153 
on the broad framework for analysis.  154 
The qualitative data from the audio-recordings were further transformed into quantitative data 155 
using the Quanti-Qualitative Appointment Timing Approach (Q-QAT). Q-QAT quantified time 156 
spent on discussions of retention during the trial consultation [12].. Q-QAT data combining cross-157 
case and within-case analysis was made across sites, trial surgeons (TSs) and research nurse 158 
(RNs) to observe changes in discussion patterns, information provision and retention rates as per 159 
previous descriptions [12]. Consideration of consultation duration (in minutes) was facilitated 160 




Sample Characteristics  165 
Thirty eight audio-recorded trial consultations from four sites were secured. Important to note that  166 
1 participants trial consultation was split across 2 audio-recordings, therefore the 38 recordings 167 
represent discussion involving 37 potential trial participants. A total of 44 participants across the 168 
four sites were included in the consultations; three research nurses (RNs), four trial surgeons (TSs) 169 
and the 37 potential trial participants. Consultations varied across the four sites in terms of health 170 




and research nurse present and one site having only a research nurse included in the audio-172 
recording (see Table 1). Consultations lasted between three and 43 minutes (median 16 minutes). 173 
Figure 1 displays the median total duration of consultations (in minutes) by site, illustrating that 174 
conversations typically lasted for 20 to 25 minutes, with Site D shorter by approximately 13 minutes 175 
compared to other sites.    176 
 177 
Time spent discussing retention 178 
Of the 38 consultations, only 8 (11%) included any discussion about trial retention (see Table 1).  179 
From these eight consultations where retention was discussed, the proportion of time spent 180 
discussing retention ranged from 0.76% to 13.3% with a median of 3.8% across all consultations 181 
where retention was discussed (Table 1).   182 
 183 
There was variation across the sites as to whether retention was discussed at all and if so how 184 
long it was discussed for (Figure 2 presents discussion of retention as a proportion of total 185 
consult time). Site A had no discussions of any aspect relating to trial retention present in the 186 
trial consultations. The other three sites all discussed retention to some extent across the 187 
sampled consultations.  When considered as a proportion of total consultation time by site these 188 
retention discussions ranged from 0.27% to 2.95% of the total consultation time (Figure 2). The 189 
longest discussion about retention within a consultation, from across all sites, was 89 seconds 190 
and the shortest 20 seconds.  Of the three sites that did discuss retention, some discussed it 191 
more frequently than others (see Table 1). Site B performed best with 62.5% of consultations 192 
analysed featuring discussions of retention, Site D had 20% of consultations presenting 193 
discussion of retention, and Site C with 10% of consultations discussing retention. 194 
 195 
Content of discussions about retention 196 
Broad analysis of the content of the consultations covering retention identified that 12.5% 197 
contained inaccuracies, 12.5% failed to detail the frequency of follow-up questionnaires to be 198 
completed, 25% were discussion prompted by participants, and 50% contained an imbalanced 199 
focused on patient’s rights to withdraw.  200 
When considering details of how retention was discussed across consultation included in this 201 
analysis, we identified examples of ‘good’ and ‘could do better’ practice.  To first consider the ‘could 202 
do better’, these discussions largely focussed on process based information relating to the timing 203 





Timing and purpose of questionnaires 206 
Across all consultations where retention was discussed the timing and purpose of the 207 
questionnaires was mentioned. Some specified all time points (3, 9, 12, 18 months) and stated the 208 
mode of delivery (postal questionnaire) where as others provided incorrect information or were 209 
more vague about mode or indeed which participants would be followed up. 210 
“So with the quality of life, I mentioned there was a baseline - and with those forms you’ll get sent 211 
one 3 months, 9 , 12, and 18 …..” “They will be very similar to the baseline ones if you want to go 212 
into the study. And the study centre will send those out” Research Nurse Site B 213 
 214 
‘Surgeon: Umm I mean you can always say uhh uhh that ah regardless of which treatment group you 215 
do - the study allocates to you , for example if it says observation then uh you will uh will require 216 
observation in about 3 months’ time. Is that right?” (Doctor asking research nurse) 217 
Research Nurse: "Umm yeah, we just send you the questionnaire by email or by phone - so you will 218 
just answer them every couple of months. That’s all we will do. There is nothing where you physically 219 
have to come or need to be examined or anything like that" Site C 220 
 221 
“Emm what we do is that we send you a questionnaire in the post. 3, 6, 9, 12, and 18 months. So it’s 222 
every 3 months you get questions in the post. Kind of day to day thing about how your pain is and 223 
things and such. It does not involve another visit back for us. Emm, If you do get randomized to 224 
surgery – emm, it’s a  kind of a standard way to check for that. And then we also send you the 225 
questionnaires in the post as well.’ Surgeon Site D 226 
 227 
Participant’s right to withdraw 228 
Within the limited conversations about retention there was time spent highlighting to participants 229 
that they had the right to withdraw from the trial at any time, that there decision was flexible but 230 
without providing any  information on the consequences. 231 
 232 
“Like Mr X said, it is a randomized controlled study - so if somebody agrees to go into the study there 233 
is some baseline information that we do when they consent.  So there is a consent process that I’d go 234 
through. Umm a consent form that you fill in. And you can withdraw your consent at any time. So if 235 
you fill in your consent from today, decided you wanted to do it - and then went home, thought 236 
about it - and thought, actually no this isn’t right for me; you can withdraw at any time. Umm and 237 
again with the follow ups - so the follow up questionnaires you can always decide that when life gets 238 




too much other things going on - again you can choose to withdraw from the follow up as well. So if 240 
you decide to go into the study it is not set in stone. You can withdraw at any time alright?.” 241 
Research Nurse Site B 242 
 243 
There were some examples of ‘good’ practice within the consultations analysed.  As previously 244 
highlighted informing participants of the timing and mode of delivery of the questionnaires was one. 245 
Another was  sharing the questionnaires with participants during the consent discussion to give 246 
them an idea of what was expected of them.  247 
 248 
"With the follow-up, it’s the same for both arms for the questionnaires. I will show you a copy so you 249 
know what is expected of you. This is the baseline. But it is the same for all of them. There is no 250 
massive essays. It’s a tick box - and I don’t know if you want to have a look through that. Umm it’s all 251 
about the general health, following activities of daily living, discussing pain…” Research Nurse Site B 252 
 253 
Another example from the conversations during the consent process highlighted that completion 254 
and return of the questionnaires can also be considered as a proxy for continued consent to the 255 
trial.  256 
 257 
‘That’s pretty good, perfect! And the questionnaire don’t forget the questionnaires. In a way that is 258 
kind of confirming your on-going consent’ Surgeon Site B      259 
 260 
Participant prompted discussions 261 
In addition to the examples of ‘good’ and ‘could do better’ practice identified within the 262 
consultations, there was also a sense that some of the conversations (2 out of the 8) relating to 263 
retention were prompted by potential trial participants. One potential trial participant was 264 
concerned about whether participating in the trial would affect pre-planned travel. With another 265 
asking abut what the expectations were across the course of the trial. 266 
 267 
Impact of discussions of retention on consent to the trial 268 
As these consultations are audio-recorded when the trial is introduced to the potential 269 
participant and a decision about participation is made, we investigated whether discussions of 270 
retention were associated with decisions to participate in the trial.  The majority (n=22, 60%) of 271 
the participants included in the sample for this study declined participation in the main trial 272 




the 15 participants who did consent to participate in the main trial, seven of these consultations 274 
(47%) included discussions of retention where as eight (53%) did not.  However, if we consider 275 
the participation behavior of those participants for whom retention was discussed (a total of 276 
eight consultations), seven (87.5%) went on to consent to trial participation and only one (12.5%) 277 
declined.  Unsurprisingly the majority of consultations fell into the category that did not consent 278 
to the main trial and did not discuss retention (n= 21, 55 %) with only one consultations across 279 
the 38 declining participation in trial where the consultation included a discussion of retention 280 
(see Table 1).  281 
 282 
Impact of discussion on retention to return of postal questionnaires 283 
To determine whether duration of retention discussions was linked to return of postal 284 
questionnaire we rank ordered the sites according to duration of retention discussions and 285 
compared this to their response rates for questionnaire return to explore potential association. 286 
Despite Site A having no discussion of retention in relation to total consult time (0%) (Figure 2), it 287 
had the greatest questionnaire response of 98% at three months and 81% at nine months (Table 288 
2). Site B had the highest proportion of consultation time devoted to discussions about retention 289 
and was ranked second in terms of questionnaire response (80% at both the three and nine 290 
months). Whilst sites C and D discussed retention (albeit at a limited level), the questionnaire 291 
return rates were also poor at both time points.   See Table 2 for site summary of consultations 292 
with discussions of retention and postal questionnaire return. There was no indication of an 293 
association between duration of discussions of retention and overall questionnaire response 294 
rates across sites.  However, it is of interest to note that Site D, who had the lowest median 295 
consultation time, also performed the worst with regard to overall questionnaire response rates.  296 
 297 
Discussion  298 
Key Findings  299 
We believe this to be the first embedded mixed method study to investigate clinical trial 300 
consultations for discussion of trial retention. Key findings revealed a lack of discussions of retention 301 
across the majority (79%) of consultations analysed. Furthermore, the findings suggests that almost 302 
half of the consenting participants were not provided with opportunities to discuss aspects of 303 
retention that may be important for their decision to participate.  Of the 21% of consultations 304 
where discussions of retention were present, some contained inaccuracies, lacked critical details, 305 




withdraw.   All of this brings into question the adequacy of trial consultations in supporting informed 307 
choices about trial participation. 308 
 309 
Our findings resonate with data from a recent study that analysed 50 patient information leaflets 310 
(PILs) for clinical trials across a cohort of publically funded UK based RCTs [7]. This analysis of PILs 311 
identified that retention is often poorly described within this written information with an 312 
unbalanced focus on the patients right to withdraw (present in 98% of the PILs analysed) without 313 
having to give a reason (90%) [7].  Contrastingly, only 16% of the PILs analysed included statements 314 
on the value and importance of retention [7]. This focus on the right to withdraw without providing 315 
information about the consequences of such behaviour for the trial mirrors the findings from our 316 
study with regard to the verbal information provided in the consultations.  This echo chamber effect 317 
may not be that surprising if we consider that much of the international guidance relating to 318 
informed consent for clinical trials (from the Declaration of Helsinki) does not go further than 319 
specifying that trial participants ‘must be informed of the right to refuse to participate in the study 320 
or to withdraw consent to participate at any time without reprisal.’ [13].   This is also specified in the 321 
ICH GCP legislative guideline on informed consent for trials but it does also state that participants 322 
should be informed of the ‘expected duration of their participation’ – which does talk to aspects of 323 
retention [14].  Finally, the guidance on PILs produced from the UKs Health Research Authority 324 
highlights the importance of including information that covers what the participant will have to do 325 
and what it will mean to them to take part, but does not specify this is in relation to retention, in 326 
addition to these previous items [15].  All of these guidance documents are largely considering 327 
information provided to participant in written format. In line with this international and national 328 
guidance, the parent trial included in our study had minimal written information in relation to trial 329 
retention. Whilst this changed as a consequence of the findings of this study,  it also allows 330 
inferences about discussions of retention and actual behaviour of participants to hold more weight. 331 
Therefore,expectation setting and discussions about consequences  of poor retention perhaps need 332 
to be framed in a conversation. There may be promise in using a summary sheet of the key aspects 333 
for discussion (which would include retention and its importance) as a prompt to remind staff but 334 
also as a take-away reminder for the potential participant within the PIL.   335 
 336 
A recent priority setting exercise with the trials community to identify research questions of 337 
importance for retention in trials has also identified the issue of what information should be 338 
communicated to potential trial participants to improve retention as a top 10 priority for future 339 




(by patients, trialists, clinicians) that also implicitly require information and conversation during the 341 
informed consent process e.g. ‘how does a participant’s ongoing experience of the trial affect 342 
retention?’ and ‘what motivates a participant’s decision to complete a clinical trial’.  Efforts to 343 
address these linked priorities could enable better expectation setting from the outset for potential 344 
trial participants about what they can expect from the trial and what the trial can expect from them 345 
across its duration. 346 
 347 
We highlighted that there is a tendency for trial teams to highlight the right for participants to 348 
withdraw at any time without giving a reason but there was no matched information on the 349 
consequences of what that means for the trial. A requirement for including information about the 350 
consequences of not completing a trial, or possibly reframed as the potential benefits of completing 351 
all follow up activities would also link back to expectation setting.  Evidence from the treatment and 352 
screening decision making literature supports the notion that to enable informed choices to be 353 
made, patients must be aware of all of the consequences relating to the decision they are 354 
considering [16]. In the context of a clinical trial, this would include information about participating 355 
or not and completing the trial or not. Preliminary evidence suggests that the inclusion of this type 356 
of information has a positive impact on reducing trial drop-out rates but more research is needed 357 
[17]. The acceptability of including this type of consequential information in PILs has been explored 358 
amongst a range of stakeholders [18]. It was shown that Ethics Committee Members felt this type of 359 
information could be perceived as potentially coercive however patients felt the information was 360 
well balanced and supported decision making [18]. Therefore, any adjustments to the retention 361 
information with a focus on consequences would need buy in from a range of stakeholders.  Further 362 
analysis of trial consultations to explore whether the decision to participate (if expressed early in a 363 
consultation) then goes on to predict whether discussions of retention (and indeed other important 364 
aspects of trial participation) are discussed and the duration of these discussions.  In other words, is 365 
non-consent also as informed as consent in these settings. 366 
 367 
Our study focused on the verbal information provided in the initial trial consultation and showed 368 
that this was lacking with regard to retention.  Whilst appropriate written information can act as a 369 
framework to support this conversation, training for staff involved in these discussions would also 370 
be key. Recent studies have highlighted the need to support and train staff involved in retention 371 
noting that the focus on recruitment can be detrimental to this endeavour [19]. There are now well 372 
established programmes to train health professionals to recruit to trials [20]. This training has been 373 




and an increase in recruitment to trials [20, 21]. However, to date, these training packages have 375 
largely focused their content on recruitment. Including key aspects of retention (e.g. potential 376 
research set backs caused by missing data and the significance of completing follow-up procedures) 377 
as a core component of this training would be a valuable addition. Careful consideration in relation 378 
to outcomes of importance for these training packages is also required.  To date, outcomes have 379 
focussed on trainer related or trial specific outcomes [20]. Yet some assessment of how the process 380 
was for the potential trial participants should also be central if considering aspects of the informed 381 
consent process.  Work in this area to determine a core outcome set for evaluating interventions to 382 
improve informed consent to trials is ongoing [22]. 383 
 384 
Strengths and Limitations 385 
The main limitation of the study is that the analysis included a sample of conversations from one 386 
trial. Significant further work involving a larger sample size (aggregated across several trials from 387 
varying contexts) that is sufficiently powered to detect any difference would be required in order 388 
to determine causality. This study does not claim to present any causal inference, but rather is 389 
an initial exploration of whether and how retention is discussed in initial consultations about 390 
clinical trial participation..  In addition, no assessment of data saturation was made (largely due 391 
to the minimal data available within the discussions) and therefore analysis of a larger number of 392 




 It is of particular importance to note that all trial follow-up was captured through postal 394 
questionnaires which were administered through the trial study office and not a responsibility of the 395 
trial teams involved in the initial trial consultations.  Therefore it could have modified the sense of 396 
responsibility with regard to follow up. In addition, it might be that recordings of the consultations 397 
may not have captured the entire trial conversations that occurred between potential participants 398 
and the site trial teams. Therefore, it is possible relevant data was missing from the data collected.  399 
However it is important to highlight that during the trial initiation training given to all sites it is 400 
specifically requested that audio recordings capture the entirety of the consultation. 401 
Embedding a mixed-methods methodological evaluation within a clinical trial context maximises 402 
opportunities to identify (and resolve) problems with trial conduct.  A significant strength of this 403 
piece of work is the real time capture of data during trial consultations to analyse discussions about 404 
retention, rather than relying on personal accounts of the process in interviews after the event. In 405 
addition, by investigating consultations from a multi-centre trial with various sites we were able to 406 
examine an array of generic and site-specific discussion inadequacies. Hence, such features may be 407 
likely to be transferable to other trials in other settings.   408 
 409 
 Conclusion 410 
This research provides evidence of the lack of discussion about trial retention during  consultations 411 
for a surgical RCT. It Ddraws further impetus to calls to focus on retention during recruitment and 412 
not just worry about it when it becomes a problem.  Ways to tackle these deficits could include 413 
changes to the written and verbal information provided to participants during the initial 414 
consultation, training for staff to ensure key aspects are covered, discussions with regulatory and 415 
oversight bodies to ensure recommendations are deemed appropriate, and generating 416 
interventions that are centred in accounts from participants. Getting some of these solutions in 417 
place will allow trialists to design and deliver trials that retain the participants they work so hard to 418 
recruit. 419 
 420 
What’s New 421 
Our study has revealed that trial staff may provide imbalanced information abut retention during 422 
the consultation process for potential participants. Thus, adjustments must be made to the current 423 
consultation style and supported with adequate written information. It should be noted that equal 424 
time should be spent discussing all key issues listed, alongside participants rights and responsibilities 425 
to ensure coercion is avoided. Previous studies have cited the need for recognition of the 426 




organisations, we would also echo this call [19]. Such a shift in expectations at the highest level, may 428 
provide clinicians the encouragement to adjust the on-going strain between upholding informed 429 
decision-making for participants and meeting target recruitment. Thus, a shift in priority could 430 
inspire a clinical trial culture concerned with maintaining consent (and the communication 431 
strategies to do so) as opposed to simply obtaining it. 432 
Further research replicating this study across a range of trials is welcome and needed to ensure the 433 
findings presented here are replicable and  transferable to other settings.  In addition, exploring 434 
how best to communicate information relating to retention with participants should also be a 435 
recommendation going forward. Ultimately participant-centred retention interventions should be 436 
developed that are embedded in participants accounts and co-designed with those who are the 437 
end-users. 438 
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